RecruitingNCT05234177

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Tempus CRC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Colorectal Cancer (CRC) Using Comprehensive Next-Generation Sequencing (NGS)Assays

Sponsor

Tempus AI

Enrollment

300 participants

Start Date

Jun 21, 2022

Study Type

OBSERVATIONAL

Conditions

Colorectal, Cancer

Summary

The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Known or suspected colorectal adenocarcinoma (Stage I to IVA disease)
Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent.
years old or older
Willing and able to provide informed consent
Willing to have additional blood samples collected during routine surveillance visits

Exclusion Criteria2

Not willing to have additional blood samples collected
Pathology that is not consistent with colorectal adenocarcinoma

Interventions

OTHERObservation

No intervention

Locations(20)

Mercy Clinic Oncology - Fort Smith

Fort Smith, Arkansas, United States

MemorialCare

Fountain Valley, California, United States

The Center for Cancer and Blood Disorders

Bethesda, Maryland, United States

Mercy Clinic Oncology and Hematology - Joplin

Joplin, Missouri, United States

Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center

Springfield, Missouri, United States

Washington University School of Medicine

St Louis, Missouri, United States

Mercy Clinic Oncology and Hematology - Sindelar Cancer Center

St Louis, Missouri, United States

Mercy Clinic Oncology and Hematology - David C. Pratt Cancer Center

St Louis, Missouri, United States

Nebraska Cancer Specialists

Omaha, Nebraska, United States

Southeastern Medical Oncology Center

Goldsboro, North Carolina, United States

Aultman Hospital

Canton, Ohio, United States

TriHealth Cancer Institute

Cincinnati, Ohio, United States

Ohio State University

Columbus, Ohio, United States

OhioHealth Research Institute

Columbus, Ohio, United States

Toledo Clinic Cancer Center

Toledo, Ohio, United States

Mercy Clinic Oncology and Hematology - Coletta

Oklahoma City, Oklahoma, United States

Cancer Care Associates of York

York, Pennsylvania, United States

Utah Cancer Specialists

Salt Lake City, Utah, United States

University of Washington / Fred Hutchinson Cancer Center

Seattle, Washington, United States

ThedaCare Regional Cancer Center

Appleton, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05234177

Related Trials

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

NCT0546403035 locations

Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors

NCT060775911 location

Camera Capsule Endoscopy in the Routine Diagnostic Pathway for Colorectal Diseases

NCT064755601 location

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

NCT0701157614 locations

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

NCT069922589 locations